2019
Immunotherapy for Infectious Diseases, Cancer, and Autoimmunity
Krause P, Kavathas P, Ruddle N. Immunotherapy for Infectious Diseases, Cancer, and Autoimmunity. 2019, 265-276. DOI: 10.1007/978-3-030-25553-4_16.ChaptersSubset of patientsMonoclonal antibodiesSide effectsAutoimmune side effectsRespiratory syncytial virusMinimal side effectsInitial unresponsivenessCheckpoint inhibitorsAdverse eventsField of immunologyCheckpoint inhibitionTreatment failureCytokine inhibitorsSyncytial virusAutoimmune diseasesCancer immunotherapyInhibitory receptorsLate toleranceLung cancerImmune cellsPassive transferImmune regulationImmune responseImmunotherapyLatent infection
2001
Safety and Immunogenicity of a Recombinant Borrelia burgdorferi Outer Surface Protein A Vaccine Against Lyme Disease in Healthy Children and Adolescents: A Randomized Controlled Trial
Sikand V, Halsey N, Krause P, Sood S, Geller R, Van Hoecke C, Buscarino C, Parenti D. Safety and Immunogenicity of a Recombinant Borrelia burgdorferi Outer Surface Protein A Vaccine Against Lyme Disease in Healthy Children and Adolescents: A Randomized Controlled Trial. Pediatrics 2001, 108: 123-128. PMID: 11433064, DOI: 10.1542/peds.108.1.123.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntigens, SurfaceArthralgiaBacterial Outer Membrane ProteinsBacterial VaccinesBorrelia burgdorferi GroupChildChild, PreschoolEdemaErythemaExanthemaFatigueFemaleFeverHeadacheHumansImmunoglobulin GIncidenceInjectionsLipoproteinsLyme DiseaseLyme Disease VaccinesMalePainSeverity of Illness IndexTime FactorsUnited StatesConceptsLocal injection site reactionsInjection site reactionsYears of ageMonth 13LD vaccineVaccine recipientsSite reactionsHealthy childrenEfficacy studiesChildren 4Placebo-controlled clinical trialUnsolicited adverse eventsFlu-like symptomsLyme disease vaccineHigher immune responseLyme endemic areasOuter Surface ProteinsAdolescents 15 yearsIgG GMTPlacebo recipientsReactogenicity dataAdverse eventsControlled TrialsMonth 6Immunogenicity data